Episode Summary
Today A/Prof Rachel Roberts-Thomson discusses Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer. A/Prof Rachel Roberts-Thomson is joined by A/Prof Venessa Chin and Angeline Low who has her own personal experience with EGFR lung cancer .
EGFR mutations are identified in approximately 15% of NSCLC patients. Efficacious, PBS-reimbursed first line treatments are available, but resistance to treatment and progression remains a concern. In this podcast, options for treatment post-progression are discussed, including accessible treatment and sequencing options and the role of patient preferences and clinical trials.
In collaboration/partnership/supported with/by Roche.
Disclaimer: The opinions, beliefs and viewpoints expressed by the various authors and participants contained in this message do not necessarily reflect the opinions, beliefs and viewpoints of TOGA or official policies of TOGA. Dosage & administration of any treatments mentioned during TOGA medical education may differ between Regions. Please refer to your local prescribing information for further details.
Note: SRS is Stereotactic radiosurgery
Show Hosts
This episode’s host are:
- A/Prof Rachel Roberts-Thomson, Medical Oncologist, The Queen Elizabeth Hospital and Cancer Care Adelaide
- A/Prof Venessa Chin, Medical Oncologist and Post-doctoral Research Officer, St Vincent’s Hospital Sydney and The Garvan Institute of Medical Research
- Angeline Low
